Today: 30 April 2026
DBS stock price ends week near a 52-week high as Fed decision and Feb 9 earnings loom
25 January 2026
1 min read

DBS stock price ends week near a 52-week high as Fed decision and Feb 9 earnings loom

SINGAPORE, Jan 25, 2026, 14:48 SGT — Market closed

  • DBS shares closed up 1% at S$58.65, lingering just 1% below their 52-week high
  • After the Bank of Japan held steady, global rate signals drew fresh scrutiny ahead of the Fed’s January 27-28 meeting
  • DBS will report its fourth-quarter results on Feb 9, with investors closely watching margins and dividends.

DBS Group Holdings Ltd shares ended Friday at S$58.65, gaining 0.98% after moving between S$57.90 and S$58.83 earlier in the day. The stock is still about 1% below its 52-week high of S$59.25.

This change matters because rate forecasts could shift once more this week, affecting bank valuations directly. DBS will report its quarterly results in two weeks, where it must outline its perspective on what “normal” earnings mean as borrowing costs ease.

Asian risk appetite improved Friday after the Bank of Japan kept rates unchanged but revised its growth and inflation forecasts upward, hinting at possible gradual tightening ahead. “The tone appears hawkish,” said David Chao, global market strategist for Asia-Pacific at Invesco in Singapore. Reuters

For DBS, the spotlight remains firmly on net interest margin — the difference between what it earns on loans and pays on deposits. In the latest quarter, both DBS and Singapore peer UOB reported margin squeeze as interest rates softened, a headache investors have yet to shake off.

All eyes are on the U.S. Federal Reserve’s Jan. 27-28 meeting, with the policy decision and press conference set for Jan. 28. Any shift in the Fed’s language could ripple through global rate markets and alter banks’ lending spreads.

DBS will unveil its fourth-quarter 2025 results on Feb. 9. Investors are focused on margin pressure, credit costs, and the bank’s strategy for capital returns—particularly the dividend it intends to uphold throughout the current cycle.

The setup still holds risks. Should interest rates fall more quickly than anticipated, margins could tighten. Plus, a slowdown in regional growth might push bad-loan charges higher, eating into earnings that appear stable—right up until they don’t.

The stock’s next key moment arrives Monday in the Singapore session, with traders watching global rates and Asia FX closely after the BOJ’s announcement. The bigger milestone, though, is Feb. 9, when DBS rolls out its report and new data lands for investors to weigh.

Stock Market Today

  • Why This ASX 200 Biotech Stock Is Under Pressure
    April 30, 2026, 3:23 PM EDT. The ASX 200 biotech sector is facing pressure amid recent market developments. Key factors include regulatory challenges and clinical trial setbacks affecting investor sentiment. This volatility impacts stock valuations and trading volumes, highlighting risks within the biotech industry. Investors are advised to monitor updates carefully and consult financial professionals before making decisions. Recent movements underscore the sector's sensitivity to news flow and operational progress.

Latest article

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

30 April 2026
Stellantis reported a first-quarter net profit of €377 million, reversing a €387 million loss a year earlier, aided by a €400 million expected U.S. tariff refund. Industrial free cash flow remained negative at €1.92 billion. Shares fell 6.4% to €6.22 after the results. CEO Antonio Filosa faces pressure ahead of a May 21 investor day to present a stronger turnaround plan.
Nanya Technology stock price: T$2.05 bln equipment buy keeps Taiwan DRAM maker in focus ahead of Monday
Previous Story

Nanya Technology stock price: T$2.05 bln equipment buy keeps Taiwan DRAM maker in focus ahead of Monday

CapitaLand Investment stock price at S$3.05: what to watch before SGX reopens Monday
Next Story

CapitaLand Investment stock price at S$3.05: what to watch before SGX reopens Monday

Go toTop